Home About us Contact | |||
Clinical Studies Show (clinical + studies_show)
Selected AbstractsAndrogen Decreases Dopamine Neurone Survival in Rat MidbrainJOURNAL OF NEUROENDOCRINOLOGY, Issue 4 2010M. L. Johnson Clinical studies show that men are more likely to develop disorders affecting midbrain dopaminergic pathways, such as drug addiction and Parkinson's disease (PD). Although a great deal of focus has been given to the role of oestrogen in the maintenance of midbrain dopaminergic pathways, little is known about how testosterone influences these pathways. In the present study, we used stereological analysis of tyrosine hydroxylase-immunoreactive (TH-IR) cell bodies to determine how testosterone influences the dopaminergic cell bodies of the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA). Rats and mice were castrated at postnatal day (PN) 60, and these midbrain cell populations were counted on PN 90. One month after castration, TH-IR cell number had increased in the SNpc and VTA of rats and mice. Replacement with testosterone or the non-aromatisable analogue dihydrotestosterone (DHT) in castrated animals reduced TH-IR cell number in the SNpc and VTA in rats. In mice, the decrease of TH-IR cell number with testosterone or DHT replacement was observed only in the SNpc. The apparent increase in TH-IR neurone number after castration is not explained by an increase in TH expression because the number of nondopaminergic cells (TH-immunonegative, TH-IN) did not decrease proportionally after castration. TH-IN cell number did not change after castration or hormone replacement in rat or mouse SNpc or VTA. These findings suggest that testosterone may play a suppressive role in midbrain dopaminergic pathways. [source] Aging stimulates cyclooxygenase-2 expression and prostaglandin E2 production in human periodontal ligament cells after the application of compressive forceJOURNAL OF PERIODONTAL RESEARCH, Issue 1 2007Kotoe Mayahara Background and Objectives:, Some clinical studies show that alveolar crestal bone loss is higher in adults than in young patients during orthodontic treatment, but the causes of such a phenomenon have not been elucidated. It is known that prostaglandin E2 (PGE2) is a proinflammatory agent and one of the potent osteoclast-inducing factors, and is produced by human periodontal ligament cells in response to orthodontic force. The aim of this study was to investigate age-related change in the biosynthetic capacity of PGE2 and its regulatory gene, cyclooxygenase 2 (COX-2) from periodontal ligament cells in response to mechanical stress. Methods:, Compressive force of 2 g/cm2 was applied for 3,48 h to periodontal ligament cells obtained from human donors aged 9,50 years, and COX-2 mRNA expression in and PGE2 production by the periodontal ligament cells in response to the compressive force were examined. Results:, Application of a compressive force of 2 g/cm2 for 3,48 h significantly stimulated these factors in both time- and age-dependent manners. Furthermore, these increases were dramatically larger in periodontal ligament cells obtained from donors over the age of 35. Conclusions:, Periodontal ligament cells obtained from old donors have significantly greater COX-2 expression and PGE2 production in response to compressive force than those from younger donors. The turning point of aging, where significantly larger amounts of theses factors begin production, appears to be around the age of 35. These results may be positively related to the acceleration of alveolar crestal bone loss during orthodontic treatment in adult patients. [source] Intentional weight loss and mortality among initially healthy men and womenNUTRITION REVIEWS, Issue 7 2008Mette K Simonsen Most prospective observational studies suggest that weight loss increases the risk of premature death among obese individuals. This is surprising because clinical studies show that weight loss generally leads to overall improvements in cardiovascular risk factors. It is sometimes argued that the increased mortality observed with weight loss must depend on confounding or poor study designs. This review was conducted to summarize results from studies on intentional weight loss and mortality among healthy individuals, while carefully considering the designs and problems in these studies. Evaluation criteria with a rating scale were developed. Of the studies evaluated, two found decreased mortality with intentional weight loss, three found increased mortality, and four found no significant associations between intentional weight loss and total mortality. Thus, it is still not possible for health authorities to make secure recommendations on intentional weight loss. More studies designed to specifically address this issue are warranted. [source] Reperfusion and calculated RISKs: pharmacological postconditioning of human myocardiumBRITISH JOURNAL OF PHARMACOLOGY, Issue 1 2008G F Baxter The last five years have witnessed a remarkable resurgence of interest in myocardial reperfusion injury. Reperfusion is absolutely essential to salvage ischaemic myocardium but experimental and clinical studies show that reperfusion-associated injury may mask the full benefits of prompt reperfusion in acute myocardial infarction. In the current issue of the British Journal of Pharmacology, Mudalagiri et al demonstrate a protective effect against simulated reperfusion injury using exogenously applied erythropoietin in human isolated myocardium. Crucially, the benefits of erythropoietin were observed when it was administered specifically during re-oxygenation. The demonstration that the protective effects of the cytokine were dependent on PI3-kinase/Akt and ERK1/2 activation provides compelling evidence that reperfusion injury salvage kinases (RISKs) are key survival mechanisms in human myocardium, as they are in experimental animal species. Although erythropoietin may be only one of several potential pharmacological approaches in human patients, this study establishes the important proof-of-principle that activation of RISKs is protective in human myocardium and could be a promising therapeutic target in acute myocardial infarction. British Journal of Pharmacology (2008) 153, 1,3; doi:10.1038/sj.bjp.0707498; published online 22 October 2007 [source] |